ArticleAnnals of surgical oncology2026
High PARP7 Expression is Associated with Higher Estrogen Response and Immune Suppression but Less Cell Proliferation and Better Survival in Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: PARP7 Association to Estrogen and Immunity in Clinical Breast Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVarious poly(ADP-ribose) polymerases (PARPs) are known to be related to DNA repair, and PARP7 has been linked to estrogen signaling and immunity. Recently, PARP7 was shown to increase cancer cell proliferation, but reports are conflicting. Given that these studies are mostly based on in vitro experiments, this study investigated how PARP7 expression impacts breast cancer patients.
methodsClinical and transcriptomic data of breast cancer patients were obtained from the METABRIC (n = 1904), TCGA (n = 1090), and SCAN-B (n = 3069) cohorts. The median value was used to divide the cohorts into high- and low-PARP7 groups.
resultsHigh PARP7 expression was significantly associated with better overall survival in two of the three cohorts (p < 0.05), and PARP7 was expressed predominantly by epithelial cells (p < 0.001). Estrogen receptor (ER)-positive breast cancer had a higher expression of PARP7 than other subtypes (p < 0.001). High PARP7 expression was associated with high estrogen and androgen response consistently in all cohorts. Tumors expressing higher PARP7 levels had significantly lower mutation rates, neoantigens, type 1 interferon (IFN-1), and immune cell infiltration in (p < 0.001). High PARP7 expression was associated with less enrichment of cell proliferation-related gene sets (E2F targets, G2M checkpoint, and MYC targets), in all cohorts. Higher PARP7 expression was associated with less cancer cell proliferation, lower tumor grade, and lower Ki67 (p < 0.001).
conclusionHigh PARP7 expression is associated with estrogen and androgen response, but also with better overall survival and lower cell proliferation.
Indexed as
Identifiers
41712159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.